January 8, 2018 / 12:10 PM / 5 months ago

BRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies

Jan 8 (Reuters) - Simcere Pharmaceutical Group (IPO-SMPT.HK):

* MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES

* MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING CO’S BICLONICS TECHNOLOGY PLATFORM

* MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS

* MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE

* MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS

* MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below